Juve-cal

Artemisia Abrotanum Flowering Top, Phosphoric Acid, Silver Nitrate, Barium Carbonate, Lycopodium Clavatum Spore, Delphinium Staphisagria Seed, Calcium Hypophosphite, And Cinchona Officinalis Bark


Pekana Naturheilmittel Gmbh
Human Otc Drug
NDC 59469-310
Juve-cal also known as Artemisia Abrotanum Flowering Top, Phosphoric Acid, Silver Nitrate, Barium Carbonate, Lycopodium Clavatum Spore, Delphinium Staphisagria Seed, Calcium Hypophosphite, And Cinchona Officinalis Bark is a human otc drug labeled by 'Pekana Naturheilmittel Gmbh'. National Drug Code (NDC) number for Juve-cal is 59469-310. This drug is available in dosage form of Syrup. The names of the active, medicinal ingredients in Juve-cal drug includes Artemisia Abrotanum Flowering Top - 8 [hp_X]/250mL Barium Carbonate - 12 [hp_X]/250mL Calcium Hypophosphite - 4 [hp_X]/250mL Cinchona Officinalis Bark - 8 [hp_X]/250mL Delphinium Staphisagria Seed - 6 [hp_X]/250mL Lycopodium Clavatum Spore - 12 [hp_X]/250mL Phosphoric Acid - 4 [hp_X]/250mL Silver Nitrate - 6 [hp_X]/250mL . The currest status of Juve-cal drug is Active.

Drug Information:

Drug NDC: 59469-310
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Juve-cal
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Artemisia Abrotanum Flowering Top, Phosphoric Acid, Silver Nitrate, Barium Carbonate, Lycopodium Clavatum Spore, Delphinium Staphisagria Seed, Calcium Hypophosphite, And Cinchona Officinalis Bark
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Pekana Naturheilmittel Gmbh
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Syrup
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ARTEMISIA ABROTANUM FLOWERING TOP - 8 [hp_X]/250mL
BARIUM CARBONATE - 12 [hp_X]/250mL
CALCIUM HYPOPHOSPHITE - 4 [hp_X]/250mL
CINCHONA OFFICINALIS BARK - 8 [hp_X]/250mL
DELPHINIUM STAPHISAGRIA SEED - 6 [hp_X]/250mL
LYCOPODIUM CLAVATUM SPORE - 12 [hp_X]/250mL
PHOSPHORIC ACID - 4 [hp_X]/250mL
SILVER NITRATE - 6 [hp_X]/250mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 24 Jun, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:PEKANA Naturheilmittel GmbH
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:QG07G580U0
6P669D8HQ8
CUI83R2732
S003A158SB
00543AP1JV
C88X29Y479
E4GA8884NN
95IT3W8JZE
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Blood Coagulation Factor [EPC]
Calcium [CS]
Cations
Divalent [CS]
Increased Coagulation Factor Activity [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
59469-310-501 BOTTLE, GLASS in 1 BOX (59469-310-50) / 250 mL in 1 BOTTLE, GLASS24 Jun, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

For occasional minor fatigue and exhaustion. application of this homeopathic remedy for the designated usage is exclusively based on homeopathic experience. with severe forms of this disease, a clinically proven therapy is indicated.

Product Elements:

Juve-cal artemisia abrotanum flowering top, phosphoric acid, silver nitrate, barium carbonate, lycopodium clavatum spore, delphinium staphisagria seed, calcium hypophosphite, and cinchona officinalis bark artemisia abrotanum flowering top artemisia abrotanum flowering top phosphoric acid phosphoric acid silver nitrate silver cation barium carbonate barium cation lycopodium clavatum spore lycopodium clavatum spore delphinium staphisagria seed delphinium staphisagria seed calcium hypophosphite calcium cation cinchona officinalis bark cinchona officinalis bark water alcohol

Indications and Usage:

Indications for occasional minor fatigue and exhaustion. application of this homeopathic remedy for the designated usage is exclusively based on homeopathic experience. with severe forms of this disease, a clinically proven therapy is indicated.

Warnings:

Warning if symptoms persist, contact a licensed practitioner. if you have known sensitivity to any of the ingredients, please consult your licensed practitioner before use. if you are pregnant or nursing a baby, seek the advice of a health care professional before use. keep out of the reach of children.

Dosage and Administration:

Dosage unless otherwise prescribed, adults take 1 to 2 teaspoons, 2 to 3 times per day, measured in a calibrated dosing cup. for pediatric doses, consult your practitioner.

Package Label Principal Display Panel:

Principal display panel - 250 ml bottle box juve-cal™ oral drops homeopathic medicine for occasional minor fatigue and exhaustion 8.5 fl. oz. (250ml) pekana ® principal display panel - 250 ml bottle box

Further Questions:

To report adverse events, contact bioresource at 321b blodgett street, cotati, ca 94931


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.